Gene expression profiles at different stages of collagen-induced arthritis

Autoimmunity

Volumn 41, Issue 7, 2008, Pages 512-521

  Booth, George ^a   Newham, Peter ^a   Barlow, Rachel ^a   Raines, Stephanie ^a   Zheng, Biao ^b   Han, Shuhua ^b  

^a NHS Trust United Kingdom   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmunity; Chemokines; Collagen induced arthritis; Gene expression

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; CXCL13 CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; IMMUNOPATHOGENESIS; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; UNINDEXED SEQUENCE; UPREGULATION;

EID: 54549103634     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930802095210     Document Type: Article

References (47)

1. Myers, LK, Rosloniec, EF, Cremer, MA and Kang, AH (1997) Collagen-induced arthritis, an animal model of autoimmunity. Life Sci, 61:19, pp. 1861-1878.
2. Edwards, JC, Cambridge, G. and Abrahams, VM (1999) Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology, 97:2, pp. 188-196.
3. Looney, RJ, Anolik, JH, Campbell, D., Felgar, RE, Young, F., Arend, LJ, Sloand, JA, Rosenblatt, J. and Sanz, I. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum, 50:8, pp. 2580-2589.
4. Svensson, L., Jirholt, J., Holmdahl, R. and Jansson, L. (1998) B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol, 111:3, pp. 521-526.
5. Stuart, JM and Dixon, FJ (1983) Serum transfer of collagen-induced arthritis in mice. J Exp Med, 158:2, pp. 378-392.
6. Holmdahl, R., Andersson, M., Goldschmidt, TJ, Gustafsson, K., Jansson, L. and Mo, JA (1990) Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev, 118, pp. 193-232.
7. van den Berg, WB (2000) Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis, 59, pp. i81-i84.
8. Maini, RN and Taylor, PC (2000) Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med, 51, pp. 207-229.
9. Gracie, JA, Forsey, RJ, Chan, WL, Gilmour, A., Leung, BP, Greer, MR, Kennedy, K., Carter, R., Wei, XQ Xu, D. et al. (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest, 104:10, pp. 1393-1401.
10. Walmsley, M., Katsikis, PD, Abney, E., Parry, S., Williams, RO, Maini, RN and Feldmann, M. (1996) Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum, 39:3, pp. 495-503.
11. Hermann, JA, Hall, MA, Maini, RN, Feldmann, M. and Brennan, FM (1998) Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum, 41:8, pp. 1388-1397.
12. Triantaphyllopoulos, KA, Williams, RO, Tailor, H. and Chernajovsky, Y. (1999) Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum, 42:1, pp. 90-99.
13. Lubberts, E., Joosten, LA, Chabaud, M., van Den Bersselaar, L, Oppers, B., Coenen-De Roo, CJ, Richards, CD, Miossec, P. and van Den Berg, WB (2000) IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest, 105:12, pp. 1697-1710.
14. Ibrahim, SM, Koczan, D. and Thiesen, HJ (2002) Gene-expression profile of collagen-induced arthritis. J Autoimmun, 18:2, pp. 159-167.
15. Thornton, S., Sowders, D., Aronow, B., Witte, DP, Brunner, HI, Giannini, EH and Hirsch, R. (2002) DNA microarray analysis reveals novel gene expression profiles in collagen-induced arthritis. Clin Immunol, 105:2, pp. 155-168.
16. Gierer, P., Ibrahim, S., Mittlmeier, T., Koczan, D., Moeller, S., Landes, J., Gradl, G. and Vollmar, B. (2005) Gene expression profile and synovial microcirculation at early stages of collagen-induced arthritis. Arthritis Res Ther, 7:4, pp. R868-R876.
17. Han, S., Cao, S., Bheekha-Escura, R. and Zheng, B. (2001) Germinal center reaction in the joints of mice with collagen-induced arthritis: An animal model of lymphocyte activation and differentiation in arthritis joints. PG-1438-43. Arthritis Rheum, 44:6, pp. 1438-1443.
18. Storey, JD (2002) A direct approach to false discovery rates. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 64:3, pp. 479-498.
19. Ludwig, A., Hundhausen, C., Lambert, MH, Broadway, N., Andrews, RC, Bickett, DM, Leesnitzer, MA and Becherer, JD (2005) Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen, 8:2, pp. 161-171.
20. White, JM (2003) ADAMs: Modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol, 15:5, pp. 598-606.
21. Parks, WC, Wilson, CL and Lopez-Boado, YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol, 4:8, pp. 617-629.
22. Chirco, R., Liu, XW, Jung, KK and Kim, HR (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev, 25:1, pp. 99-113.
23. Baker, AH, Edwards, DR and Murphy, G. (2002) Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci, 115, pp. 3719-3727.
24. Ansel, KM, Ngo, VN, Hyman, PL, Luther, SA, Forster, R., Sedgwick, JD, Browning, JL, Lipp, M. and Cyster, JG (2000) A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature, 406:6793, pp. 309-314.
25. Blades, MC, Ingegnoli, F., Wheller, SK, Manzo, A., Wahid, S., Panayi, GS, Perretti, M. and Pitzalis, C. (2002) Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum, 46:3, pp. 824-836.
26. Hargreaves, DC, Hyman, PL, Lu, TT, Ngo, VN, Bidgol, A., Suzuki, G., Zou, YR, Littman, DR and Cyster, JG (2001) A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med, 194:1, pp. 45-56.
27. Ben-Baruch, A., Xu, L., Young, PR, Bengali, K., Oppenheim, JJ and Wang, JM (1995) Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage inflammatory protein-1 alpha/Rantes, is also a functional receptor for MCP3. J Biol Chem, 270:38, pp. 22123-22128.
28. Sternlicht, MD and Werb, Z. (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 17, pp. 463-516.
29. Gough, PJ, Garton, KJ, Wille, PT, Rychlewski, M., Dempsey, PJ and Raines, EW (2004) A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol, 172:6, pp. 3678-3685.
30. Hakak, Y., Shrestha, D., Goegel, MC, Behan, DP and Chalmers, DT (2003) Global analysis of G-protein-coupled receptor signaling in human tissues. FEBS Lett, 550:13, pp. 11-17.
31. Sallusto, F., Lenig, D., Mackay, CR and Lanzavecchia, A. (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med, 187:6, pp. 875-883.
32. Bonecchi, R., Bianchi, G., Bordignon, PP, D'Ambrosio, D., Lang, R., Borsatti, A., Sozzani, S., Allavena, P., Gray, PA Mantovani, A. et al. (1998) Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med, 187:1, pp. 129-134.
33. Onuffer, JJ and Horuk, R. (2002) Chemokines, chemokine receptors and small-molecule antagonists: Recent developments. Trends Pharmacol Sci, 23:10, pp. 459-467.
34. Schroder, AE, Greiner, A., Seyfert, C. and Berek, C. (1996) Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA, 93:1, pp. 221-225.
35. Luther, SA, Lopez, T., Bai, W., Hanahan, D. and Cyster, JG (2000) BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity, 12:5, pp. 471-481.
36. Zheng, B., Ozen, Z., Zhang, X., De Silva, S., Marinova, E., Guo, L., Wansley, D., Huston, DP, West, MR and Han, S. (2005) CXCL13 neutralization reduces the severity of collagen-induced arthritis. Arthritis Rheum, 52:2, pp. 620-626.
37. Sallusto, F., Lenig, D., Forster, R., Lipp, M. and Lanzavecchia, A. (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature, 401:6754, pp. 708-712.
38. Rollins, BJ (1997) Chemokines. Blood, 90:3, pp. 909-928.
39. Fong, AM, Robinson, LA, Steeber, DA, Tedder, TF, Yoshie, O., Imai, T. and Patel, DD (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med, 188:8, pp. 1413-1419.
40. Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H. Schall, TJ et al. (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell, 91:4, pp. 521-530.
41. Ruth, JH, Volin, MV, Haines 3rd, GK, Woodruff, DC, Katschke Jr., KJ, Woods, JM, Park, CC, Morel, JC and Koch, AE (2001) Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum, 44:7, pp. 1568-1581.
42. Hromas, R., Broxmeyer, HE, Kim, C., Nakshatri, H., Christopherson 2nd, K., Azam, M. and Hou, YH (1999) Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun, 255:3, pp. 703-706.
43. Lindberg, J., af Klint, E, Catrina, AI, Nilsson, P., Klareskog, L., Ulfgren, AK and Lundeberg, J. (2006) Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther, 8:6, p. R179.
44. Kurth, I., Willimann, K., Schaerli, P., Hunziker, T., Clark-Lewis, I. and Moser, B. (2001) Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med, 194:6, pp. 855-861.
45. Sleeman, MA, Fraser, JK, Murison, JG, Kelly, SL, Prestidge, RL, Palmer, DJ, Watson, JD and Kumble, KD (2000) B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine. Int Immunol, 12:5, pp. 677-689.
46. Shurin, GV, Ferris, R., Tourkova, IL, Perez, L., Lokshin, A., Balkir, L., Collins, B., Chatta, GS and Shurin, MR (2005) Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol, 174:9, pp. 5490-5498.
47. Schaerli, P., Willimann, K., Ebert, LM, Walz, A. and Moser, B. (2005) Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity, 23:3, pp. 331-342.